Zoledronic acid in nine patients with transient osteoporosis of the hip

  • Gerasimos EvangelatosEmail author
  • George E. Fragoulis
  • Alexios Iliopoulos
Letters of Biomedical and Clinical Research


Transient osteoporosis (TO) is a metabolic bone disorder which causes severe lower extremity pain that exacerbates on weight-bearing [1]. The hip is the most commonly affected joint [2]. In TO, several triggers lead to increased focal bone turnover and bone marrow edema [2, 3]. The gold standard diagnostic exam is magnetic resonance imaging (MRI). Although TO is considered a self-limiting disease, intense symptoms and subsequent functional impairment might last several months and can lead in prolonged immobilization. Moreover, one-third of the patients experience migration to another joint (migratory osteoporosis) [3, 4, 5]. Despite many authors suggest only conservative treatment with analgesics and avoidance of weight-bearing, in many cases, a more targeted pharmacological intervention is used [6, 7, 8, 9]. We aimed to evaluate the effectiveness and safety of zoledronic acid (ZA) infusion in patients with TO of the hip (TOH), as well as the sustainability of the therapeutic...


Compliance with ethical standards




  1. 1.
    Asadipooya K, Graves L, Greene LW (2017) Transient osteoporosis of the hip: review of the literature. Osteoporos Int 28:1805–1816. CrossRefPubMedGoogle Scholar
  2. 2.
    Patel S (2014) Primary bone marrow oedema syndromes. Rheumatology (Oxford) 53:785–792. CrossRefGoogle Scholar
  3. 3.
    Trevisan C, Klumpp R, Compagnoni R (2016) Risk factors in transient osteoporosis: a retrospective study on 23 cases. Clin Rheumatol 35:2517–2522. CrossRefPubMedGoogle Scholar
  4. 4.
    Singh D, Ferrero A, Rose B, Goldberg A, Cullen N (2016) Bone marrow edema syndrome of the foot and ankle: mid- to long-term follow-up in 18 patients. Foot Ankle Spec 9:218–226. CrossRefPubMedGoogle Scholar
  5. 5.
    Evangelatos G, Fragoulis GE, Zampeli E, Kechagia M, Iliopoulos A (2019) Zoledronic acid is effective and safe in migratory osteoporosis. Rheumatology (Oxford).
  6. 6.
    Emad Y, Ragab Y, El-Shaarawy N, Rasker JJ (2012) Transient osteoporosis of the hip, complete resolution after treatment with alendronate as observed by MRI description of eight cases and review of the literature. Clin Rheumatol 31:1641–1647. CrossRefPubMedGoogle Scholar
  7. 7.
    Flores-Robles BJ, Sanz-Sanz J, Sanabria-Sanchinel AA, Huntley-Pascual D, Andreu Sanchez JL, Campos Esteban J, Blanco R, Merino-Argumanez C, Espinosa-Malpartida M, Ramos-Giraldez MC, Godoy-Tundidor H, Jimenez-Palop MM, Barbadillo Mateos C, Villa-Alcazar LF, Isasi CM, Mulero JB (2017) Zoledronic acid treatment in primary bone marrow edema syndrome. J Pain Palliat Care Pharmacother 31:52–56. CrossRefPubMedGoogle Scholar
  8. 8.
    Varenna M, Zucchi F, Binelli L, Failoni S, Gallazzi M, Sinigaglia L (2002) Intravenous pamidronate in the treatment of transient osteoporosis of the hip. Bone 31:96–101CrossRefGoogle Scholar
  9. 9.
    Kibbi L, Touma Z, Khoury N, Arayssi T (2008) Oral bisphosphonates in treatment of transient osteoporosis. Clin Rheumatol 27:529–532. CrossRefPubMedGoogle Scholar
  10. 10.
    Kotwal A, Hurtado MD, Sfeir JG, Wermers RA (2019) Transient osteoporosis: clinical spectrum in adults and associated risk factors. Endocr Pract. CrossRefGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2019

Authors and Affiliations

  1. 1.Rheumatology Department417 Army Share Fund Hospital (NIMTS)AthensGreece
  2. 2.Rheumatology Unit, First Department of Propaedeutic Internal Medicine, School of MedicineNational and Kapodistrian University of AthensAthensGreece

Personalised recommendations